For broader research context on nootropic compounds, including comparative stacks, cycling considerations, and interaction notes, see the Complete Nootropic Cheat Sheet.
What Is Bromantane?
Bromantane (Ladasten) is a synthetic adamantane derivative with a unique dual pharmacological profile: it combines dopaminergic stimulation with anxiolytic activity — a combination rarely seen in single compounds. Developed in the Soviet Union as a neuroadaptogen for personnel operating under extreme stress, it has been used clinically in Russia for asthenic conditions and fatigue syndromes.
Mechanism of Action
Bromantane's primary mechanism is the upregulation of dopamine synthesis enzymes — specifically tyrosine hydroxylase (TH) and DOPA decarboxylase — in the dopaminergic pathways of the brain. Unlike classical stimulants that block reuptake or force release, Bromantane increases the capacity to produce dopamine, creating a more sustainable form of dopaminergic enhancement. It also appears to modulate GABA-A receptor sensitivity, contributing to anxiolytic effects without sedation.
Performance and Safety
Animal studies show Bromantane increases exercise tolerance, reduces fatigue, and improves coordination under both physical and cognitive stress. Importantly, it does not produce the cardiovascular effects, appetite suppression, or dependency potential of classical stimulants — making it distinct from conventional psychostimulants.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Actoprotector Bromantane (Ladasten)
Morozov, I.S., Ivanova, I.A., Lukicheva, T.A., 2001, Bulletin of Experimental Biology and Medicine - Toxic effect of single treatment with bromantane on neurological status of experimental animals
Iezhitsa, I.N., Spasov, A.A., Bugaeva, L.I., 2002, Bulletin of Experimental Biology and Medicine - The effect of bromantane on the dopamine synthesis and metabolism in the rat striatum
Kudrin, V.S., Klodt, P.M., Narkevich, V.B., et al., 2007, Eksperimental'naia i Klinicheskaia Farmakologiia - The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats
Mikhaylova, M.A., Kulikov, A.V., Kudrin, V.S., et al., 2007, Neuropharmacology - The effect of bromantane on the behavior of inbred mouse strains with different phenotypes of emotional stress reaction
Iezhitsa, I.N., Spasov, A.A., Bugaeva, L.I., 1999, Eksperimental'naia i Klinicheskaia Farmakologiia - Pharmacological characteristics of a new actoprotector, bromantane
Bobkov, Yu.G., Morozov, I.S., Glozman, O.M., et al., 1984, Bulletin of Experimental Biology and Medicine - Clinical and pharmacokinetic study of the new psychoactive drug Ladasten
Zherdev, V.P., Neznamov, G.G., Siuniakov, S.A., et al., 2009, Vestnik Rossiiskoi Akademii Meditsinskikh Nauk - Treatment of asthenic disorders in patients with psychoautonomic syndrome: results of a multicenter study on efficacy and safety of ladasten
Siuniakov, S.A., Grishin, S.A., Teleshova, E.S., et al., 2011, Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova